secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0001104659-25-078665
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025
--------------------------------------------------------------------------------

- Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.
- Basic EPS of $0.51; diluted EPS loss of $1.00.
- R&D expenses $5.8M (down $0.7M YoY); G&A expenses $3.1M (up $2.4M due to merger costs).
- Cash, equivalents, and short-term investments $41.0M as of June 30, 2025; runway into Q4 2026.
- REVERT IPF Phase 2 trial fully enrolled; topline data expected Q4 2025. IND for TTI-109 submitted to FDA in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/0001104659-25-078665-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-078665

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer